22 Jul Orca Bio
Dan Kirby, Chief Commercial Officer
Oct. 10 | 5:15pm | Ecolab Life Sciences Ballroom
Menlo Park, CA
Orca Bio is a clinical-stage cell therapy company engineering high-precision cell therapies designed to replace patients’ diseased blood and immune system with healthy ones for the treatment of cancer, genetic blood disorders and autoimmune diseases. Today, we’re focused on redefining the traditional stem cell transplant by developing cell therapies that provide significantly better outcomes with dramatically fewer toxicities, like GvHD, for patients. Our lead investigational high-precision cell therapy, called Orca-T, is currently being evaluated in a pivotal Phase 3 clinical trial for the treatment of blood cancers and other hematological malignancies. In parallel, we’re advancing our next-generation programs to expand our pipeline to bring cell therapy to all patients who could benefit, including potential future application in autoimmune disease and genetic disorders. Our mission is to make curative cell therapies both safer and more effective, and in doing so, push past the field’s current boundaries and redefine its future.